Simcere Pharmaceutical Group Renews Key Agreements
MT Newswires Live2024-12-24
Simcere Pharmaceutical Group (HKG:2096) renewed two key agreements set to expire on Dec. 31 including a three-year Diagnostics R&D Project Service Framework Agreement with Jiangsu Medical Diagnostics from January 1, according to a Monday filing with the Hong Kong bourse.
Similarly, a property lease and services framework with Nanjing BioSciKin Technology will offer office, laboratory, and staff facilities as well as logistical support.
Both transactions are classified as continuing connected transactions under Hong Kong's Listing Rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.